Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) reported a narrower third-quarter 2026 net loss as revenue increased and research and development expenses declined. Net loss was approximately $3.2 million, versus $3.6 million a year earlier; revenue rose to approximately $48,000 from $2,300. Cash and cash equivalents were approximately $11.5 million, with working capital of approximately $3.2 million at September 30.
The company expects DARE to PLAY prescription dispensing in November 2026 in 28 states, following prescriptions written across 48 states and Washington, D.C. Flora Sync LF5 began generating sales in July. Daré expects 2026 product revenue to be immaterial and targets DARE to RECLAIM dispensing in 2027. Ovaprene Phase 3 and DARE-HPV Phase 2 topline results are anticipated in 2027. Daré has secured more than $75 million in non-dilutive grant awards and is exploring collaborations for its programmable drug-delivery platform.
Daré Bioscience (NASDAQ: DARE) received an additional $851,796 payment under its existing grant agreement supporting development of a non-hormonal intravaginal contraceptive.
The payment is the second-to-last anticipated tranche under an up to approximately $10.7 million agreement announced in November 2024. The research targets unmet contraceptive needs in low- and middle-income countries. Daré previously received approximately $5.4 million in 2024 to support the ongoing Phase 3 study of Ovaprene, its investigational hormone-free monthly contraceptive, followed by approximately $3.6 million in November 2025. Future funding remains contingent on achieving additional milestones specified in the agreement.
Daré Bioscience (DARE) will host its third-quarter financial results conference call and webcast on November 16, 2026, at 4:30 PM Eastern Time.
The call will review results for the quarter ended September 30, 2026, and provide a company update. The webcast will be available through the investor website, with a replay archived for 90 days.
Daré Bioscience (DARE) released a new CEO Corner video featuring founder, president and CEO Sabrina Martucci Johnson discussing its commercial transition. FloraSync LF5 is now available, and the company expects prescription dispensing of DARE to PLAY Sildenafil Cream to begin this quarter. The discussion covers potential growth drivers, anticipated clinical milestones and products advancing toward commercialization. The episode is available on the company’s website for approximately 90 days after its initial release.
Daré Bioscience (NASDAQ: DARE) is scheduled to present at Stifel’s 2026 Healthcare Conference on November 11, 2026, in New York. Founder, President and Chief Executive Officer Sabrina Martucci Johnson will speak from 11:20 a.m. to 11:50 a.m. ET at the Lotte New York Palace Hotel.
The presentation will cover the company’s women’s health portfolio, commercial strategy and clinical pipeline. A live webcast will be publicly accessible, with a replay available through the company’s investor website for 90 days.
Daré Bioscience (DARE) received a $1.5 million grant installment to support continued preclinical development of its investigational contraceptive program DARE-LARC1.
Total non-dilutive funding received under the agreement is approximately $43.3 million. The remaining approximately $5.6 million of the up to approximately $48.9 million commitment depends on future development milestones and other requirements. Funding supports nonclinical studies and activities intended to support an Investigational New Drug application, a request to begin human clinical testing.
The company is exploring potential collaborations to evaluate its DARE-IDDS drug delivery platform in additional therapeutic areas, including obesity and diabetes.
Daré Bioscience (NASDAQ: DARE) participated in a Virtual Investor discussion about the recent executive order addressing women’s health research and care.
CEO Sabrina Martucci Johnson discussed the potential significance of the October 19, 2026 order, which established a White House Women’s Health Task Force and directed the creation of a Women’s Health Division within NIH. The discussion also covered Daré’s commercial strategy and pipeline, including anticipated prescription dispensing of DARE to PLAY Sildenafil Cream this quarter. The segment is available for on-demand viewing.
Daré Bioscience (NASDAQ: DARE) will present its investigational DARE-IDDS drug-delivery device at PODD on October 30, 2026, in Boston. Vice President of Product Development Liz Proos will speak from 2:30 to 2:50 p.m. ET.
The implantable device is designed to deliver more than 100 discrete doses over months to years, with programmable dosing and wireless communication. Its initial development target is contraception through the DARE-LARC1 program. DARE-IDDS remains in preclinical development; its described features are based on technological proof-of-concept studies. It is not approved or cleared for human clinical investigation or any human use.
Daré Bioscience (NASDAQ: DARE) announced its premier sponsorship of Managing Menopause After Breast Cancer, an educational program scheduled for October 20, 2026.
Presented by HERmedicine and the OncoMenopause Consortium in San Diego, the continuing medical education program will cover hormonal and nonhormonal treatment approaches, sexual health, and quality of life after breast cancer. Daré also plans to present a scientific poster with data from a Phase 1 study of investigational Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Society’s 2026 Annual Meeting, held October 20–24, 2026.
Daré Bioscience (DARE) launched CEO Corner, a video series featuring Founder, President and CEO Sabrina Martucci Johnson for investors. The inaugural episode introduces the series and explains its role in sharing context behind the company’s strategy beyond formal announcements.
The company plans future episodes covering its commercial portfolio, clinical development programs, upcoming milestones and approach to long-term value creation in women’s health. The latest episode is available at darebioscience.com/ceocorner and will remain accessible for approximately 90 days after its initial release.